YALE UNIVERSITY
Fighting
Pneumonia.
With a $1.5 Million Grant, YSPH Scientist Seeks to Improve
Vaccine Delivery in Developing World.
While considerable progress has been made in
improving children’s health globally, pneumococcus remains a stubborn problem.
The bacterium is a major cause of pneumonia,
the world’s leading cause of respiratory deaths in children under age 5. The
vast majority of those deaths occur in the developing world, where the vaccine
is expensive, and has not been widely introduced.
With a $1.5 million grant from the Bill &
Melinda Gates Foundation, a team of Yale School of Public Health researchers
led by Daniel Weinberger, Ph.D., assistant professor in the Department of
Epidemiology of Microbial Diseases, is poised to shed light on how the
potentially life-saving vaccine could impact low-income communities
worldwide.
“There is still a lot of uncertainty about
how this vaccine will impact resource-poor communities,” Weinberger said. “Our
study will provide new information about how socioeconomic conditions might
influence vaccine impacts.”
The study will seek to analyze a complex set
of hospitalization and administrative data on pneumonia in order to understand
the varying effectiveness of vaccination on different socioeconomic groups. The
research will begin by examining data from Latin America, where the vaccine has
a foothold, and then use that information to develop models of the vaccine’s
potential impact in similar low- and middle-income communities where the
vaccine has yet to be introduced and where there is a lack of high-quality
data.
“I would hope that our results will help to
provide important information to policymakers about the potential impacts of
the vaccine, and they could then use these data to make informed decisions
about whether to support the introduction and continued use of the vaccine in
their countries, ” Weinberger said.
His team will also develop graphical
visualization tools that will help local leaders without quantitative expertise
understand the potential impacts of the vaccine in their settings and use data
to inform effective policy decisions.
Based on evidence from North America, Europe
and other regions where the vaccine is more widely used, vaccinating children
against pneumococcus is the most effective way to prevent pneumococcal
infections in both children and adults, Weinberger said. A particular benefit
of vaccinating children is “herd protection,” which sees disease rates drop
among the elderly and other high-risk groups when children are vaccinated. The
study will look at how the effects of the vaccine and herd protection could
change between various socioeconomic groups.
Pneumonia, particularly in children, is an
area of focus for the Bill & Melinda Gates Foundation, which places strong
emphasis on improving health care in the developing world. Weinberger and his
team will share the study’s results with the foundation, as well as with the
World Health Organization.
“The Gates Foundation is great at connecting
researchers and policy makers working in similar areas to ensure that the
research is relevant and will have an impact on policy,” Weinberger said.
